GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation

The next generation Androgen receptor (AR)-targeted therapies are now in widespread clinical use and prolong prostate cancer (CaP) patient survival. However, the therapies are not curative due to diverse range of resistance mechanisms. AR variants (AR-V), one major mechanism of resistance, has recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Bing, Zhang, Lijuan, Liu, Shenglin, Chen, Xiaofan, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872515/
https://www.ncbi.nlm.nih.gov/pubmed/31803623
http://dx.doi.org/10.3389/fonc.2019.01254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872515/
https://www.ncbi.nlm.nih.gov/pubmed/31803623
http://dx.doi.org/10.3389/fonc.2019.01254

Ejemplares similares